Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg



Status:Recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:2/6/2019
Start Date:March 14, 2018
End Date:March 1, 2024
Contact:Trial Specialist
Email:medinfo@bmrn.com

Use our guide to learn which trials are right for you!

Phase 3 Study To Evaluate Efficacy/Safety of Valoctocogene Roxaparvovec an AAV Vector-Mediated Gene Transfer of hFVIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels ≤1IU/dL Receiving Prophylactic FVIII Infusions

This clinical trial is being conducted to learn more about a potential treatment
(valoctocogene roxaparvovec) for people with severe hemophilia A. This research study will
test and confirm the safety and effectiveness of the 4E13 vg/kg dose of the study drug
(valoctocogene roxaparvovec) that contains the correct gene to make Factor VIII so that the
body can make its own Factor VIII that functions properly. Only one dose of valoctocogene
roxaparvovec is being given in this study, and this dose has been previously studied in
another clinical trial in patients with hemophilia A. This is a phase 3 study which is meant
to show that the study drug is safe and works to help treat hemophilia A. The study will see
if liver cells are able to make Factor VIII that functions properly after receiving this
study drug. The study will also examine the effects that the study drug has on how much
Factor VIII concentrates patients have to inject into their veins and on their bleeding
episodes after the study drug has been administered. Finally, the study will see if and how
the body responds to the study drug - for example, whether liver cells become inflamed or
whether the body makes antibodies (something the immune system makes to protect itself
against things like bacteria and viruses) against the vector or the new Factor VIII gene.


Inclusion Criteria:

- Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as
evidenced by medical history, at the time of signing the informed consent.

- Must have been on prophylactic FVIII replacement therapy for at least 12 months prior
to study entry. High-quality, well-documented historical data concerning bleeding
episodes and FVIII usage over the previous 12 months must be available.

- Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure
days (EDs).

- No previous documented history of a detectable FVIII inhibitor, and results from a
Bethesda assay or Bethesda assay with Nijmegen modification of less than 0.6 Bethesda
Units (BU) (or less than 1.0 BU for laboratories with a historical lower sensitivity
cutoff for inhibitor detection of 1.0 BU) on 2 consecutive occasions at least one week
apart within the past 12 months (at least one of which should be tested at the central
laboratory).

Exclusion Criteria:

- Detectable pre-existing antibodies to the AAV5 capsid.

- Any evidence of active infection or any immunosuppressive disorder, including HIV
infection.

- Significant liver dysfunction with any of the following abnormal laboratory results:

- ALT (alanine aminotransferase) > 1.25x ULN;

- AST (aspartate aminotransferase) > 1.25x ULN;

- GGT (gamma-glutamyltransferase) >1.25x ULN

- Total bilirubin >1.25x ULN;

- Alkaline phosphatase >1.25x ULN; or

- INR (international normalized ratio) ≥ 1.4.

Subjects whose liver laboratory assessments fall outside of these ranges may undergo repeat
testing of the entire liver test panel within the same Screening window and, if eligibility
criteria are met on retest, may be enrolled after confirmation by the Medical Monitor.

- Prior liver biopsy showing significant fibrosis of 3 or 4 as rated on a scale of 0-4
on the Batts Ludwig (Batts 1995) or METAVIR (Bedossa 1996) scoring systems, or an
equivalent grade of fibrosis if an alternative scale is used.

- Evidence of any bleeding disorder not related to hemophilia A.

- Platelet count of < 100 x 10^9/L.

- Creatinine ≥ 1.5 mg/dL.

- Liver cirrhosis of any etiology as assessed by liver ultrasound.

- Chronic or active hepatitis B as evidenced by positive serology testing and
confirmatory HBV DNA testing. Refer to the Centers for Disease Control (CDC) table for
the interpretation of serological test results in the Laboratory Manual.

- Active Hepatitis C as evidenced by detectable HCV RNA or currently on antiviral
therapy.

- Active malignancy, except non-melanoma skin cancer.

- History of hepatic malignancy.
We found this trial at
21
sites
3800 Reservoir Road Northwest
Washington, District of Columbia 20007
Phone: 800-983-4587
?
mi
from
Washington,
Click here to add this to my saved trials
700 Childrens Drive
Columbus, Ohio 43205
(616) 722-2000
Phone: 800-983-4587
Nationwide Children's Hospital At Nationwide Children’s, we are creating the future of pediatric health care....
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Phone: 800-983-4587
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Phone: 800-983-4587
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Phone: 800-983-4587
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Adelaide,
Phone: 1-800-983-4587
?
mi
from
Adelaide,
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Phone: 800-983-4587
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Aurora, Colorado 80045
Phone: 800-983-4587
?
mi
from
Aurora, CO
Click here to add this to my saved trials
170 Manning Drive
Chapel Hill, North Carolina 27517
Phone: 800-983-4587
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
1653 W. Congress Parkway
Chicago, Illinois 60612
(312) 942-5000
Phone: 800-983-4587
Rush University Medical Center Rush University Medical Center encompasses a 664-bed hospital serving adults and...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
4201 St Antoine St
Detroit, Michigan 48201
(313) 577-1429
Phone: 800-983-4587
Wayne State University/Detroit Medical Center Founded in 1868, the Wayne State University School of Medicine...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
East Lansing, Michigan 48824
Phone: 800-983-4587
?
mi
from
East Lansing, MI
Click here to add this to my saved trials
2033 Mowry Road
Gainesville, Florida 32610
Phone: 800-983-4587
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
New Orleans, Louisiana 70112
Phone: 800-983-4587
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
Palo Alto, California 94304
Phone: 800-983-4587
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15213
Phone: 800-983-4587
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
2315 Stockton Blvd
Sacramento, California 95817
Phone: 800-983-4587
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
660 South Euclid Avenue
Saint Louis, Missouri 63110
Phone: 800-983-4587
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Diego, California 92093
Phone: 800-983-4587
?
mi
from
San Diego, CA
Click here to add this to my saved trials
San Francisco, California 94115
Phone: 800-983-4587
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials